Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ephedrine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Nevakar
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ephedrine Sulfate Injection (“Ephedrine”) in a prefilled syringe is a widely used injectable vasopressor agent indicated for the treatment of clinically important hypotension occurring during surgery.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Ephedrine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Nevakar
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Eagle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.
Product Name : Vasopressin-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
December 29, 2021
Lead Product(s) : Arginine Vasopressin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Eagle Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Endo International
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States
Details : Company has begun shipping varenicline, a generic version of Pfizer's Chantix® (varenicline) 0.5 mg and 1 mg tablets. Varenicline is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2021
Lead Product(s) : Varenicline Tartrate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Endo International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2017
Lead Product(s) : Pimecrolimus
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 26, 2013
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 29, 2013
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2011
Lead Product(s) : Diclofenac
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PharmaKinetics Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2011
Lead Product(s) : Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PharmaKinetics Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2011
Lead Product(s) : Doxycycline
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2011
Lead Product(s) : Doxycycline
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Anapharm
Deal Size : Inapplicable
Deal Type : Inapplicable